Top Markets
Coin of the day
Liminal BioSciences Inc. Liminal BioSciences Inc.

Liminal BioSciences Inc.

LMNL
株式のランク #38952
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm,... Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
株価
$8.50
最終同期: 2023-09-26
時価総額
$719.10K
変化(1日)
0.00%
変化(1年)
0.00%
CA
取引 Liminal BioSciences Inc. (LMNL)

カテゴリー

Liminal BioSciences Inc.(LMNL)のP/B比率
2026 時点のP/B比率 TTM: 0
Liminal BioSciences Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Liminal BioSciences Inc. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE